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Background: Cardiovascular mortality is increased in patients with ankylosing spondylitis. A possible
explanation might be a more prevalent atherogenic lipid profile in patients with ankylosing spondylitis
than in the general population. It has been postulated that inflammation deteriorates the lipid profile,
thereby increasing cardiovascular risk.
Objective: To explore the association between disease activity and lipid profile in patients with ankylosing
spondylitis.
Methods: Disease activity parameters for ankylosing spondylitis and lipid levels (total cholesterol, high-
density lipoprotein cholesterol (HDLc) and triglycerides) were measured in 45 patients with ankylosing
spondylitis for 6 months after starting treatment with leflunomide or placebo. Findings in this treatment
group were compared with those in 10 patients with ankylosing spondylitis treated with etanercept. A
specialised regression model, adjusting for repeated measurements, age and sex, was used to assess the
influence of the disease activity variables on the lipid levels.
Results: Multilevel regression analyses showed significant associations between disease activity
parameters and lipid levels—for instance, an increase of 30 mm at the end of the first hour in erythrocyte
sedimentation rate was associated with a decrease of about 6% in total cholesterol level and a decrease of
about 11% in HDLc levels. Similar significant associations were found between other disease activity
parameters and lipid levels.
Conclusion: Increase in disease activity was associated with decreases in lipid levels. The decrease in HDLc
levels tended to be almost twice as large as the decrease in total cholesterol levels, resulting in a more
atherogenic lipid profile. Hence, effective treatment of disease activity in patients with ankylosing
spondylitis may lower the cardiovascular risk by improving the lipid profile.
A
nkylosing spondylitis is a chronic inflammatory disease
that affects predominantly men, starts in young
adulthood and results in immobility of the spine and
sacroiliac joints. Although the number of studies investigat-
ing mortality in ankylosing spondylitis is limited, many of
these show an increased total mortality in patients compared
with the general population.1–4 Furthermore, this increased
mortality seems to be predominantly caused by cardiovas-
cular disease (CVD), with a twofold increased cardiovascular
standard mortality.5
A possible explanation for this increased cardiovascular
risk is a higher prevalence of conventional cardiovascular risk
factors, such as a more atherogenic lipid profile.6 An
atherogenic lipid profile is characterised by a reduced level
of high-density lipoprotein cholesterol (HDLc) and increased
levels of total cholesterol, low-density lipoprotein cholesterol
and triglycerides. An important prognostic indicator for
(future) CVD is the atherogenic index, which is the ratio of
total cholesterol to HDLc.7–10
Whether or not an atherogenic lipid profile is present in
patients with ankylosing spondylitis is presently unclear.11–13
Moreover, there is growing evidence that inflammation is
associated with deterioration of the lipid profile,14 15 but so far
data for patients with ankylosing spondylitis are lacking.
Hence, we hypothesise that disease activity in inflammatory
diseases, such as ankylosing spondylitis, worsens the lipid
profile, thereby increasing the risk for (future) CVD.
Consequently, lowering the disease activity in patients with
ankylosing spondylitis may have a beneficial effect on the
lipid profile.
Two recent studies,16 17 investigating the safety and efficacy
of treatment with leflunomide and etanercept in patients
with ankylosing spondylitis, gave us the opportunity to assess
the relationship between disease activity and lipid profile in a
total of 55 patients with ankylosing spondylitis, treated with
leflunomide, etanercept or placebo.
METHODS
Patients
All patients included in the study, aged 18–70 years, fulfilled
the 1984 modified New York criteria for ankylosing spondy-
litis.18 The first population consisted of 45 consecutive
patients with ankylosing spondylitis participating in a
monocentre, randomised, double-blind, placebo-controlled
phase II trial, in which the safety and efficacy of leflunomide
were assessed.17 Thirty patients were treated with the active
compound at a daily dose of 20 mg and 15 patients received
placebo, for a duration of 24 weeks. During this period, other
pharmacological treatments were maintained stable.
Abbreviations: BASDAI, Bath Ankylosing Spondylitis Disease Activity
Index; CRP, C reactive protein; CVD, cardiovascular disease; ESR,
erythrocyte sedimentation rate; HDLc, high-density lipoprotein
cholesterol
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The findings of the aforementioned patients with ankylos-
ing spondylitis were compared with those of a second
population consisting of 10 patients with ankylosing spon-
dylitis who were treated for 6 months with etanercept
(25 mg twice weekly).18
Disease activity parameters
The Bath Ankylosing Spondylitis Global score,19 the Bath
Ankylosing Spondylitis Functional Index20 and the Bath
Ankylosing Spondylitis Disease Activity Index (BASDAI),21 all
with a scale from 0 to 10, were determined by an experienced
rheumatologist at baseline and weeks 4, 12 and 24.
Furthermore, the erythrocyte sedimentation rate (ESR) and
C reactive protein (CRP) levels were measured at baseline
and weeks 2, 4, 6, 9, 12, 16, 20 and 24. ESR was determined
with local measurement techniques and expressed in
millimetres per hour (in men ,20 mm/h and in women
,30 mm/h). CRP was measured using a turbidimetric assay
supplied by Biomedical Diagnostics (Apeldoorn, The
Netherlands) (,10 mg/l).
Lipids
Blood samples for lipid measurements were taken after an
overnight fast at baseline and weeks 2, 4, 6, 9, 12, 16, 20 and
24. Serum total cholesterol (,5.0 mmol/l) and triglycerides
(,2.2 mmol/l) were analysed by an enzymatic method using
the appropriate assays supplied by Roche Diagnostics
(Almere, The Netherlands) on a Hitachi 911 analyser
(Roche), according to the instructions of the manufacturer.
Polyethylene glycol-modified enzymes were used for assess-
ing the HDLc levels (in men .0.9 mmol/l and in women
.1.1 mmol/l). The atherogenic index was calculated as the
total cholesterol level divided by the HDLc level.
Statistics
Measuring lipid levels and disease activity parameters in a
particular population at several time points, with variable
time intervals, causes an important statistical problem—that
is, ‘‘repeated measurements within subjects’’. To adjust for
repeated measurements within subjects, a multilevel linear
regression analysis was used. This regression technique
allows for both starting levels and progression over time to
differ between patients. It calculates the regression coeffi-
cients of the progression over time of the various lipid levels,
adjusted for repeated measurements within subjects and
variable time intervals.22
Multilevel regression analysis is a longitudinal linear
regression analysis. It combines many cross-sectional linear
regression models into one model of one variable over time.
In this study, we measured the lipid levels over time and
investigated the influence of the various other variables, such
as disease activity parameters, on these lipid levels. Multilevel
regression analysis quantifies this influence, or rather the
association between the two variables, and tests it for
statistical significance. Furthermore, the observed association
between the two variables—that is, lipid levels and disease
activity parameters—was also corrected for age and sex.
One advantage of combining the cross-sectional data of the
various time points into one association is that this increases
Table 1 Baseline characteristics of participants
Leflunomide or
placebo (n = 45) Etanercept (n = 10)
Demographic features
Age (years) 42 (11) 41 (10)
Sex (male:female) 32:13 9:1
Disease activity parameters
BASG 6.4 (1.8) 6.7 (1.6)
BASFI 5.3 (1.8) 4.4 (1.9)
BASDAI 5.5 (1.4) 4.9 (1.2)
ESR (mm/h) 15 (10–31)* 37 (13–49)*
CRP (mg/l) 13 (4–40)* 11 (4.4–29.4)*
Lipids
TC (mmol/l) 4.9 (1.2) 4.4 (0.8)
HDLc (mmol/l) 1.1 (0.9–1.4)* 1.3 (0.3)
Atherogenic index 4.3 (3.1–5.5)* 3.7 (1.1)
Triglycerides (mmol/l) 1.2 (0.8–1.8)* 1.1 (0.7–1.6)*
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath
Ankylosing Spondylitis Functional Index; BASG, Bath Ankylosing
Spondylitis Global; CRP, C reactive protein; ESR, erythrocyte
sedimentation rate; HDLc, high-density lipoprotein cholesterol; TC, total
cholesterol.
*Values are mean (SD) or median (interquartile range), as applicable.
Table 2 Influence of disease activity on the lipid levels
Increase in disease
activity parameter Lipids
Absolute
change (mmol/l)
Relative
decrease (%) p Value
30 mm/h ESR TC 20.29 26.0 0.001*
HDLc 20.13 211.4 0.01*
Atherogenic index 0.29 6.8 0.09
Triglycerides 20.15 212.6 0.04*
30 mg/l CRP TC 20.18 23.8 0.001*
HDLc 20.06 25.7 0.001*
Atherogenic index 0.10 2.4 0.16
Triglycerides 20.13 210.9 0.001*
1-point BASG TC 0.01 0.1 0.79
HDLc 20.01 20.7 0.44
Atherogenic index 0.03 0.6 0.47
Triglycerides 20.05 24.4 0.01*
1-point BASFI TC 0.02 0.4 0.62
HDLc 20.02 21.7 0.25
Atherogenic index 0.08 2.0 0.19
Triglycerides 20.06 24.5 0.01*
1-point BASDAI TC 20.01 20.3 0.66
HDLc 20.00 20.4 0.71
Atherogenic index 0.01 0.2 0.87
Triglycerides 20.07 25.8 0.01*
Atherogenic index, ratio of total cholesterol (TC) to high-density lipoprotein cholesterol (HDLc); BASDAI, Bath
Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASG, Bath
Ankylosing Spondylitis Global Score; CRP, C reactive protein; ESR, erythrocyte sedimentation rate.
Influence of disease activity parameters on lipid levels, calculated using multilevel regression analyses correcting for
age, sex and repeated measurements within subjects.
*Indicates significant associations.
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the statistical power. Another important advantage of this
method is that it holds into account and corrects for the
possibility that one or a few patients with aberrant values
distort the association between lipid levels and disease
activity—that is, the above-mentioned repeated measure-
ments within subjects. If one or a few patients have, for
example, an extreme level of a certain lipid, it will not distort
the relationship this lipid has with disease activity, because
the multilevel regression analysis will look only at this
relationship and correct for the aberrant starting points.
As the primary goal of this investigation was to study the
relationship between disease activity and lipid levels, it was
not relevant whether the antirheumatic treatment altered
disease activity; hence the data of placebo-treated and
leflunomide-treated patients were put together. The findings
were compared with those of a group of 10 patients with
ankylosing spondylitis treated with etanercept, for whom
similar analyses were conducted.
As the HDLc levels, the atherogenic index and triglyceride
levels were not normally distributed, data were analysed with
the natural logarithms of these values. For clarity, the
regression coefficients for these lipids were retransformed
to geometric means. The multilevel analyses were carried out
with the statistical program MLwiN.23 A p value of (0.05 was
considered significant.
RESULTS
Patients
The first group of 45 patients with ankylosing spondylitis (13
women and 32 men), with a mean age of 42 (standard deviation
(SD) 11; range 21–66) years, was followed for 24 weeks. Nine
patients had hypertension; eight of them used antihypertensive
agents. Two patients were treated for hypercholesterolaemia.
Non-steroidal anti-inflammatory drugs were used by 39
patients and prednisone was given to one.
The findings of 10 patients with ankylosing spondylitis
(1 woman and 9 men), with a mean age of 41 (SD 10; range
28–60) years, starting treatment with etanercept, were
compared with those of the first population. One patient
was treated for type 2 diabetes mellitus, one for hypertension
and one for hypercholesterolaemia. Nine patients used non-
steroidal anti-inflammatory drugs.
All pharmacological treatments remained unchanged dur-
ing the entire observation period. Table 1 shows the baseline
characteristics, including demographic and clinical data.
Lipid levels and disease activity parameters
Figure 1 shows the lipid levels and the disease activity
parameters in patients with ankylosing spondylitis, treated
with placebo or leflunomide (n = 45). We found no sig-
nificant changes in these variables during the 24-week
observation period. The multilevel regression analyses yielded
several significant associations between lipid level progres-
sion over time and disease activity parameters; the height of
the disease activity had a significant influence on the height
of the lipid levels. Higher ESR and CRP levels were
significantly (p,0.001) associated with lower total choles-
terol levels, with regression coefficients of 20.01 and 20.01,
respectively. The ln-triglyceride levels also had an inverse
relationship with ESR and CRP, with regression coefficients
of 20.005 and 20.004, respectively. A similar relationship
was observed between ln-HDLc and ESR and CRP levels
(regression coefficients of 20.004 and 20.002, respectively).
Moreover, the disease activity parameters tended to have a
linear relationship with the atherogenic index (p = 0.09).
The relationship between disease activity parameters and
lipid levels, or the influence of disease activity on the lipid
levels, is shown in table 2 as absolute values and percentages.
The influence of ESR and CRP on HDLc levels was almost
twice as large as the effect on total cholesterol levels,
resulting in a higher atherogenic index (p,0.001).
The multilevel analyses of patients treated with etanercept
showed that an increased ESR, CRP, Bath Ankylosing
Spondylitis Global score, Bath Ankylosing Spondylitis
Functional Index and BASDAI significantly (p(0.02)
decreased the total cholesterol levels (regression coefficients
of 20.01, 20.02, 20.07, 20.12 and 20.13, respectively).
Higher ESR and CRP levels were associated with lower HDLc
and total cholesterol levels, albeit that the decrease in HDLc
was (again) twice as large as the decrease in total cholesterol
levels, resulting in a higher atherogenic index. Moreover,
increase in other disease activity parameters was also
associated with an increase in the atherogenic index; this
association did not reach significance (p.0.08).
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Figure 1 (A–C) Mean lipid levels and disease activity variables during
the 24 weeks of placebo treatment or lefunomide treatment.
Antherogenic index, TC/HDLc; BASDAI, Bath Ankylosing Spondylitis
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional
Index; BASG, Bath Ankylosing Spondylitis Global; CRP, C reactive
protein; ESR, erythrocyte sedimentation rate; HDLc, high-density
lipoprotein cholesterol; TC, total cholesterol.
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DISCUSSION
Our investigation on patients with ankylosing spondylitis
shows that higher disease activity (parameters) is associated
with lower lipid levels and vice versa. This was observed for
total cholesterol, HDLc and triglyceride levels, which were
significantly associated with disease activity parameters as
the ESR, CRP and BASDAI. Moreover, an increase in disease
activity was associated with a decrease in total cholesterol
levels and a more pronounced decrease in HDLc levels,
subsequently resulting in a more atherogenic lipid profile.
The magnitude in which disease activity influences the
lipid levels was limited, which questions its clinical relevance.
However, although the observed influence is small, it should
be noted that ankylosing spondylitis is a chronic inflamma-
tory disease, which means that this small (detrimental)
influence has a potential clinically relevant effect on the
cardiovascular risk for many years. The importance of small
differences in lipid levels over a prolonged period is best
illustrated by several studies in which cardiovascular risk
reduction was found by lowering lipid levels slightly but over
a prolonged period. Firstly, the follow-up of the Framingham
cohort showed that a lower HDLc level of just 0.25 mmol/l
was associated with a 50% higher risk for future vascular
events.24 Secondly, a landmark study on fibrates showed a
22% reduction in the risk for CVD in the group receiving the
active compound versus placebo. The group receiving the
active compound showed only small changes in lipid levels—
that is, 4% decrease in total cholesterol, 6% increase in HDLc
and 31% decrease in triglyceride levels.25 Although these
figures cannot be directly extrapolated to this study, they do
indicate the clinical relevance of small changes in lipid levels.
Growing evidence suggests that inflammation has an
important role in the pathogenesis of CVD, particularly in
atherosclerosis.26 In addition to a postulated direct effect of
inflammation on endothelial cells, mounting evidence
suggests that inflammation can also increase the cardiovas-
cular risk by deterioration of the lipid profile, which is
supported by the findings of a study showing a decrease in
HDLc and apolipoprotein A I levels and an increase in
triglyceride and apolipoprotein B levels during an acute-
phase response.27 Other investigators found an association
between an increase in lipids as oxidised low-density
lipoprotein cholesterol and proinflammatory cytokines as
CRP, interleukin 6 and tumour necrosis factor a.28 The
findings of the present study confirm these effects of
inflammation on the various lipid concentrations.
High disease activity is characterised by increased cytokine
expression and this could directly lead to altered lipid levels
through effects on the liver or adipose tissue. Moreover, there
may also be an indirect way through various intermediate
factors—for example, metabolic or dietary factors. Patients
with ankylosing spondylitis with high disease activity might
be in a metabolic state comparable to those with rheumatoid
cachexia.29 Decreasing disease activity would improve their
general well-being and physical function, with subsequent
changes in lipid levels. The results of the present study
support this hypothesis, as lower disease activity (para-
meters) was associated with a more favourable lipid profile.
This investigation is in line with the accumulating evidence
of the intriguing interactions between dyslipidaemia, athero-
sclerosis and inflammation, showing a worsening of the lipid
profile during increased disease activity. Obviously, more
prospective investigations with cardiovascular end points are
needed to further unravel these relationships.
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